Literature DB >> 23078887

Risk for coronary heart disease increases risk for colorectal neoplasm.

Ji Young Lee1, Sung Noh Hong, Jeong Hwan Kim, Won Hyeok Choe, Sun-Young Lee, In Kyung Sung, Hyung Seok Park, Chan Sup Shim.   

Abstract

BACKGROUND & AIMS: Colorectal neoplasms and coronary artery disease have similar risk factors. Patients with established coronary artery disease have a high prevalence of colorectal neoplasms. However, little is known about the risk of colorectal neoplasms among individuals at risk for coronary artery disease.
METHODS: We performed a cross-sectional study of 3144 asymptomatic, average-risk individuals without history of coronary artery disease or other vascular disorders who received a screening colonoscopy examination from January to December 2010 at Konkuk University Medical Center in Seoul, Korea. Participants were classified as having low (<10%), intermediate (10%-20%), or high (≥20%) risk for developing coronary artery disease in the next 10 years, which was based on Framingham/Adult Treatment Panel III risk scores.
RESULTS: The prevalence of colorectal neoplasms in subjects with low, intermediate, and high risk for coronary artery disease was 25.6% (635/2485), 46.6% (252/541), and 53.4% (63/118), respectively (P < .001); the prevalence of advanced colorectal neoplasms was 4.9% (122/2485), 9.2% (50/541), and 17.8% (21/118), respectively, for these subjects (P < .001). In multivariate analyses, the high-risk group had a significantly increased risk of advanced colorectal neoplasm (odds ratio, 3.31; 95% confidence interval [CI], 1.94-5.65), compared with the low-risk group. The numbers of colonoscopies needed to identify individuals with advanced colorectal neoplasms in intermediate-risk and high-risk groups were 10.8 (95% CI, 8.6-14.7) and 5.6 (95% CI, 7.6-11.9), respectively, which were significantly lower than for the low-risk group (20.4; 95% CI, 17.4-24.6).
CONCLUSIONS: The prevalence and the risk of overall and advanced colorectal neoplasms increase with risk of coronary artery disease. Individuals with a 10-year risk of coronary artery disease ≥10% might benefit from colonoscopy screening, but further studies are needed to confirm and generalize these results.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23078887     DOI: 10.1016/j.cgh.2012.10.017

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  4 in total

1.  Validation of a risk prediction score for proximal neoplasia in colorectal cancer screening: a prospective colonoscopy study.

Authors:  Martin C S Wong; Jessica Y L Ching; Victor C W Chan; Raymond S Y Tang; Arthur K C Luk; Thomas Y T Lam; Sunny S H Wong; Siew C Ng; Simon S M Ng; Justin C Y Wu; Francis K L Chan; Joseph J Y Sung
Journal:  Sci Rep       Date:  2016-02-08       Impact factor: 4.379

2.  Should screening for colorectal neoplasm be recommended in patients at high risk for coronary heart disease: a cross-sectional study.

Authors:  Sebahat Basyigit; Selcuk Ozkan; Metin Uzman; Derun T Ertugrul; Ayse Kefeli; Bora Aktas; Abdullah O Yeniova; Zeliha Asilturk; Yasar Nazligul; Hulya Simsek; Gulcin Simsek; Mehmet Ayturk; Bunyamin Yavuz
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

3.  Hyperglycemia combined Helicobacter pylori infection increases risk of synchronous colorectal adenoma and carotid artery plaque.

Authors:  Kuang-Chun Hu; Ming-Shiang Wu; Cheng-Hsin Chu; Horng-Yuan Wang; Shee-Chan Lin; Helen L Po; Ming-Jong Bair; Chuan-Chuan Liu; Tung-Hung Su; Chi-Ling Chen; Chun-Jen Liu; Shou-Chuan Shih
Journal:  Oncotarget       Date:  2017-10-26

Review 4.  How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia?

Authors:  Stepan Suchanek; Tomas Grega; Ondrej Ngo; Gabriela Vojtechova; Ondrej Majek; Petra Minarikova; Nagyija Brogyuk; Bohus Bunganic; Bohumil Seifert; Ladislav Dusek; Miroslav Zavoral
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.